Relevant bibliographies by topics / Anti-PD-1 antibodies

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Anti-PD-1 antibodies'

Author: Grafiati
Published: 4 June 2021
Last updated: 6 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Anti-PD-1 antibodies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Anti-PD-1 antibodies"

1

Abraham, Jame, and Matt Stenger. "Anti-PD-1 antibodies in melanoma." Community Oncology 10, no. 12 (2013): 342–44. http://dx.doi.org/10.12788/j.cmonc.0071.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Philips, G. K., and M. Atkins. "Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies." International Immunology 27, no. 1 (2014): 39–46. http://dx.doi.org/10.1093/intimm/dxu095.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kelsey, Rebecca. "Anti-PD-1 antibodies: effective in GCTs?" Nature Reviews Urology 13, no. 5 (2016): 238. http://dx.doi.org/10.1038/nrurol.2016.73.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Šulc, David. "Systemic treatment for metastatic uveal melanoma with anti-PD-1 antibodies." Onkologie 14, no. 1 (2020): 40–44. http://dx.doi.org/10.36290/xon.2020.011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Simeone, Ester, and Paolo A. Ascierto. "Anti-PD-1 and PD-L1 antibodies in metastatic melanoma." Melanoma Management 4, no. 4 (2017): 175–78. http://dx.doi.org/10.2217/mmt-2017-0018.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Reck, Martin. "SY4-1 Combination immunotherapy using anti-PD-1/PD-L1 plus anti-CTLA-4 antibodies." Annals of Oncology 32 (July 2021): S249. http://dx.doi.org/10.1016/j.annonc.2021.05.423.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Naidoo, J., D. B. Page, B. T. Li, et al. "Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies." Annals of Oncology 26, no. 12 (2015): 2375–91. http://dx.doi.org/10.1093/annonc/mdv383.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mellati, Mahnaz, Keith D. Eaton, Barbara M. Brooks-Worrell, et al. "Anti–PD-1 and Anti–PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes." Diabetes Care 38, no. 9 (2015): e137-e138. http://dx.doi.org/10.2337/dc15-0889.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sibaud, Vincent, Nicolas Meyer, Laurence Lamant, Emmanuelle Vigarios, Julien Mazieres, and Jean Pierre Delord. "Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies." Current Opinion in Oncology 28, no. 4 (2016): 254–63. http://dx.doi.org/10.1097/cco.0000000000000290.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Fan, Yun, and Xiaoling Xu. "Combination of anti-PD-1/PD-L1 antibodies with chemotherapy or CTL4 antibodies for first-line treatment of advanced lung cancer." Journal of Clinical Oncology 35, no. 15_suppl (2017): e20538-e20538. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e20538.

Full text
Abstract:
e20538 Background: Checkpoint inhibitors showed satisfactory efficacy in treating lung cancer. We conducted this meta-analysis to explore the therapeutic efficacy and safety of anti-PD-1/PD-L1 antibodies combine with chemotherapy or CTL4 antibodies as first-line treatment on advanced lung cancer. Methods: A quantitative meta-analysis was performed through a systematic search in PubMed, Web of Science, the conference abstracts and so on. The pooled ORR, 6-month progression-free survival rate (PFSR6m), and 1-year overall survival rate (OSR1y) were calculated and compared. 9 trials were included
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Anti-PD-1 antibodies"

1

Ben, Saad Elham. "Étude de l'endocytose du récepteur PD-1 dans les lymphocytes T humains." Thesis, 2019. http://hdl.handle.net/1866/23924.

Full text
Abstract:
PD-1 (Programmed Cell death protein -1) est un récepteur co-inhibiteur exprimé à la surface de lymphocytes T (LT) activés. Ce récepteur joue un rôle important dans le maintien de la tolérance périphérique tout en protégeant contre les maladies auto-immunes et inflammatoires. Cependant, une expression élevée et permanente de PD-1 et ses ligands PD-L1 et PD-L2 (PD-Ls) perturbe la réponse immunitaire contre les pathogènes et les cellules tumorales. Les inhibiteurs de points de contrôle immunitaires (ICI) ciblant l'axe PD-1/PD-Ls représentent aujourd’hui une avancé majeure dans le traitemen
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Anti-PD-1 antibodies"

1

Calabrò, Fabio, and Cora N. Sternberg. Treatment of metastatic bladder cancer. Edited by James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0079.

Full text
Abstract:
Although bladder cancer is considered a chemosensitive malignancy, the prognosis of patients with metastatic disease is poor, with a median survival of approximately 12–14 months in good prognosis patients and with cure in only a minority. The addition of new drugs to the standard cisplatin-based regimens has not improved these outcomes. In this chapter, we highlight the role of chemotherapy and the impact of the new targeted agents in the treatment of metastatic bladder carcinoma. A better understanding of the underlying biology and the molecular patterns of urothelial bladder cancer has led
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Anti-PD-1 antibodies"

1

Lipson, Evan J., Janis M. Taube, Lieping Chen, and Suzanne L. Topalian. "Anti-PD-1 and Anti-B7-H1/PD-L1 Monoclonal Antibodies." In Targeted Therapeutics in Melanoma. Springer New York, 2011. http://dx.doi.org/10.1007/978-1-61779-407-0_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ott, Patrick A., and F. Stephen Hodi. "T Cell Modulation: Anti-PD-1 Antibodies for the Treatment of Cancer." In Cancer Drug Discovery and Development. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-21167-1_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ayodele, Olubukola, and Lillian L. Siu. "New Drugs for Recurrent or Metastatic Nasopharyngeal Cancer." In Critical Issues in Head and Neck Oncology. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_23.

Full text
Abstract:
AbstractChemotherapy has been the backbone for the treatment of recurrent or metastatic nasopharyngeal carcinoma (RMNPC), which remains an incurable disease. Currently the most active area of therapeutic investigations in RMNPC is in immunotherapy, especially after the results of five anti-programmed death-1 (anti-PD-1) antibodies, i.e. pembrolizumab, nivolumab, camrelizumab, toripalimab and tislelizumab, have demonstrated monotherapy objective response rates of 21%–43%. Combinations using anti-PD1/L1 antibodies as backbone to evaluate their additivity or synergy with cytotoxic chemotherapy, molecularly targeted agents, or other immuno-oncology compounds are actively being developed. Besides immune checkpoint blockade, additional ways to modulate the host immune system, such as Epstein-Barr virus (EBV)-directed vaccination against viral antigens (such as EBNA1, LMP1, LMP2) with dendritic cells or peptides, adoptive cell transfer of autologous or HLA-matched allogeneic EBV-specific cytotoxic T lymphocytes, CAR or TCR T-cell therapy, personalized cancer vaccines and oncolytic viruses are being explored. Finally, novel molecularly targeted agents that have entered human testing in RMNPC include apatinib and anlotinib (antiangiogenic agents), MAK683 (an embryonic ectoderm development or EED protein inhibitor), among others. This review provides an update of ongoing clinical trials evaluating these new compounds in RMNPC.
APA, Harvard, Vancouver, ISO, and other styles
4

Patel, Anush, Haisam Abid, and Amrat Kumar. "The Endocrinological Side Effects of Immunotherapies." In Advances in Precision Medicine Oncology. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.96491.

Full text
Abstract:
The use of immunotherapies is gaining importance in the treatment of advanced malignancies. There are many checkpoints in the immune system which prevents T-cells from attacking one’s own body cells. The cancer cells can camouflage from the T-cells and the immune system is unable to mount an effective anti-tumor response. The immunotherapies, mainly monoclonal antibodies anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4), anti-programmed cell death protein-1 (PD-1) and anti-PD-1 ligand molecules (PD-L1 and L2) reactivate the immune system to act against cancerous cells but they can also cause T-cells to attack healthy cells causing various autoimmune diseases, which are known as immune related adverse events (irAEs). Current clinical data shows increased incidence of pituitary disorders with CTLA4 inhibitors and thyroid dysfunction in patients with PD-1/PD L-1 1 blockade. There have also been association of type 1 diabetes mellitus and primary adrenal insufficiency in patients with immune check point inhibitors. In this chapter we will discuss the incidence, characteristic findings, diagnosis and management of various endocrinological side effects due to targeted immunotherapies used in various malignancies.
APA, Harvard, Vancouver, ISO, and other styles
5

N. Abramson, Hanley. "Emerging Monoclonal Antibodies for the Treatment of Multiple Myeloma." In Monoclonal Antibodies [Working Title]. IntechOpen, 2020. http://dx.doi.org/10.5772/intechopen.94196.

Full text
Abstract:
Therapeutic measures designed to treat multiple myeloma (MM) have undergone a fundamental shift over the past two decades as a number of small molecules that attack this cancer by different mechanisms, including proteasome blockade, immunomodulation, and histone deacetylase (HDAC) inhibition, have been introduced. The insertion of monoclonal antibodies (mAbs) into the mix began in 2015 with the U.S. Food and Drug Administration (FDA) approval of daratumumab and elotuzumab, which target CD38 and SLAMF7, respectively. In 2020, they were joined by another anti-CD38 mAb, isatuximab, and the bispecific antibody-drug conjugate (ADC) belantamab mafodotin, which targets the B-cell maturation antigen (BCMA). This review focuses on additional mAbs currently under clinical study for MM. These include several BCMAxCD3-directed bispecifics (AMG 420, AMG 701, REGN5458, REGN5459, teclistamab, and TNB-383B), the ADCs indatuximab ravtansine and STRO-001, and checkpoint inhibitors, although the future status of the latter is in a state of flux due to toxicity issues that arose in trials in which these drugs, especially PD-1 or PD-L1 blockers, were combined with immunomodulators.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Anti-PD-1 antibodies"

1

Fujita, Kohei, Naohiro Uchida, Yuki Yamamoto, et al. "Efficacy and safety of anti-PD-L1 antibody in NSCLC patients who previously treated with anti PD-1 antibodies." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa365.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hatakeyama, Hiroto, Taiki Kurino, Reiko Matsuda, et al. "Abstract 3232: Pharmacokinetic analysis of anti-PD-1 and PD-L1 antibodies and evaluation of their anti-tumor effects." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-3232.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hatakeyama, Hiroto, Taiki Kurino, Reiko Matsuda, et al. "Abstract 3232: Pharmacokinetic analysis of anti-PD-1 and PD-L1 antibodies and evaluation of their anti-tumor effects." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-3232.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Imamura, K., R. Sato, S. Sakata, et al. "Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2456.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pachter, Jonathan A., and David T. Weaver. "Abstract B031: FAK/PYK2 inhibition enhances antitumor efficacy of anti-PD-1 and anti-4-1BB antibodies." In Abstracts: Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 25-28, 2016; New York, NY. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/2326-6066.imm2016-b031.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sánchez-Paulete, Alfonso R., Francisco J. Cueto, María Martínez-López, et al. "Abstract 4908: Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires Batf3-dependent dendritic cells." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-4908.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Burova, Elena, Omaira Allbritton, Chandrika Taduriyasas, et al. "Abstract 1484: Combined treatment with anti-LAG-3 and anti-PD-1 fully human monoclonal antibodies inhibits tumor growth in immunocompetent double-humanized LAG-3/PD-1 mice." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-1484.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

He, Daniel Xianfei, Chenpan Nie, Lei Zheng, et al. "Abstract 5614: Combination of anti-TIGIT and anti-PD-1 antibodies enhance antitumor response in a PD-1/TIGIT double HuGEMM™ model engrafted with mouse syngeneic tumors." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-5614.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Li, Baiyong, Zhaoliang Huang, Xinghua Pang, et al. "Abstract 3827: Bispecific antibodies with an anti-PD-1 backbone for cancer therapy generate enhanced immune activity." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-3827.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Tang, Jun, Laura Pearce, Jill O'Donnell-Tormey, and Vanessa M. Hubbard-Lucey. "Abstract A019: Longitudinal analysis of the landscape of cancer trials testing anti-PD-1/L1 monoclonal antibodies." In Abstracts: Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 30 - October 3, 2018; New York, NY. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/2326-6074.cricimteatiaacr18-a019.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Anti-PD-1 antibodies' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography